Regeneron Pharmaceuticals Files 8-K on Financials

TL;DR

REGN filed an 8-K for financial results, no numbers yet.

AI Summary

Regeneron Pharmaceuticals, Inc. filed an 8-K on October 7, 2024, to report on its results of operations and financial condition. The filing does not contain specific financial figures or details about the results of operations, but serves as a notification of these events.

Why It Matters

This filing indicates that Regeneron is providing updates on its financial performance and operational results to the SEC, which is important for investors to monitor.

Risk Assessment

Risk Level: low — This is a routine filing to report on financial results, not indicating any immediate adverse events.

Key Players & Entities

• REGENERON PHARMACEUTICALS, INC. (company) — Registrant
• October 7, 2024 (date) — Date of earliest event reported

FAQ

From the Filing

0001104659-24-106432.txt : 20241007 0001104659-24-106432.hdr.sgml : 20241007 20241007070027 ACCESSION NUMBER: 0001104659-24-106432 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20241007 ITEM INFORMATION: Results of Operations and Financial Condition FILED AS OF DATE: 20241007 DATE AS OF CHANGE: 20241007 FILER: COMPANY DATA: COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000872589 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 133444607 STATE OF INCORPORATION: NY FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19034 FILM NUMBER: 241356136 BUSINESS ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 BUSINESS PHONE: 9148477000 MAIL ADDRESS: STREET 1: 777 OLD SAW MILL RIVER ROAD CITY: TARRYTOWN STATE: NY ZIP: 10591 FORMER COMPANY: FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 8-K 1 tm2419098d1_8k.htm FORM 8-K false 0000872589 0000872589 2024-10-07 2024-10-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): October 7, 2024 ( October 7, 2024 )   REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter)   New York (State or other jurisdiction of incorporation)   000-19034   13-3444607 (Commission File Number)   (I.R.S. Employer Identification No.)     777 Old Saw Mill River Road , Tarrytown , New York   10591-6707 (Address of principal executive offices)   (Zip Code)   Registrant’s telephone number, including area code: ( 914 ) 847-7000   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock – par value $0.001 per share REGN NASDAQ Global Select Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 2.02.   Results of Operations and Financial Condition.   Regeneron Pharmaceuticals, Inc. (“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S. generally accepted accounting principles (“ GAAP ”) and its non-GAAP financial results for the third quarter 2024 will include an acquired in-process research and development (“ IPR&D ”) charge of approximately $56 million on a pre-tax basis. This charge relates to development milestone and up-front payments in conn